Complete the rolling submission for donanemab
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Dec 2021
- Due
- 31 Mar 2022
- Delivered
- Q2 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Lilly initiated a rolling submission for donanemab to the FDA for accelerated approval in early Alzheimer’s disease, which it expects to complete in the coming months, likely by the end of the first quarter.”
What we found
Evidence strength A What the grades mean
The company committed to completing the rolling submission by the end of Q1 2022, but filings confirm the submission was completed in the second quarter of 2022.
-
A ELI Lilly & Co 10-Q filed 2022-11-01
“Submitted in the U.S. in the second quarter of 2022.” ✓ confirmed on the page
Market reaction: the shares moved +3.8% against the S&P 500 over the three sessions around the disclosure (31 Oct 2022 to 3 Nov 2022). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Donanemab FDA submission
- Where
- USA
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LLY-004314 · Corrections policy